冷泉港亞洲：癌癥的轉(zhuǎn)化研究方法會議（蘇州）

Translational Approaches to Cancer
Suzhou, China, May 24 - 28, 2011
www.csh-asia.org

Arranged by:

Saijuan Chen, Shanghai Jiaotong University, China
David Huang, Walter & Eliza Hall Institute of Medical Research, Australia
Hiroyuki Mano, Jichi Medical University/The University of Tokyo, Japan
Yongzhang Luo, Tsinghua University, China
Scott Powers, Cold Spring Harbor Laboratory, USA

We are pleased to announce the Cold Spring Harbor Asia conference on Translational Approaches to Cancer which will be held at the Suzhou Dushu Lake Conference Center in Suzhou, China. The conference will begin at 7:30pm on the evening of Tuesday May 24th, and will conclude after lunch on Saturday May 28th, 2011.

This conference retains the essence of the prestigious Cold Spring Harbor NY meetings series, a program now in its 76th year. The conference will include eight oral sessions and one poster session. Many talks will be selected from the openly submitted abstracts on the basis of scientific merit and relevance.

Abstract:

We encourage abstracts to contain new and unpublished materials. The abstracts must be submitted electronically by the abstract deadline. Selection of material for oral and poster presentation will be made by the organizers.
Fellowship:
A certain number of presentations by graduate students and postdocs in this conference will be selected as fellowship (USD $100-$500) awards. For more details, please visit http://www.csh-asia.org/stipends.html  .

Major Topics:

- Targeted therapies in hematological malignancies
- Targeting signaling pathways in cancer
- Targeting Angiogenesis and tumor microenvironment
- Genomics and epigenomics targets in cancer
- Targeting cancer metabolism
- Molecular diagnostics & clinical trials of targeted therapeutics

Keynote Speakers

Zhu Chen, Ministry of Health P.R. China, China

Invited Speakers

Kari Alitalo, University of Helsinki, FINLAND
Edward Attiyeh, University of Pennsylvania School of Medicine, USA
Hellmut Augustin, German Cancer Research Center, GERMANY
Andrew S. Chi, Harvard Medical School, USA
Yataro Daigo, Shiga University of Medical Science, JAPAN
Frederic De Sauvage, Genentech, Inc., USA
Hugues de Thé, Université Paris 7/CNRS, FRANCE
Napoleon Ferrara, Genentech, USA
Richard Finn, UCLA Liver Cancer Center, USA
William Hahn, Dana Farber Cancer Institute / Harvard Medical School, USA
Samir Hanash, Fred Hutchinson Cancer Research Center, USA
Lars Holmgren, Karolinska Institue, SWEDEN
Raghu Kalluri, Harvard Medical School/BIDMC, USA
William Kim, The University of North Carolina at Chapel Hill School of Medicine, USA
Gangning Liang, USC/Norris Comprehensive Cancer Center, USA
Wenchu Lin, Dana-Farber Cancer Institute, USA
Hiroyuki Mano, Jichi Medical University/The University of Tokyo, JAPAN
Jian-Hua Mao, Rui-Jin Hospital affiliated to Shanghai Jiao Tong, CHINA
Ultan McDermott, Wellcome Trust Sanger Institute, UK
Wilson Miller, McGill University, CANADA
Kate Revill, Cold Spring Harbor Laboratory, USA
Charles Roberts, Dana-Farber Cancer Institute, USA
Maarten Van Lohuizen, Netherlands Cancer Institute, THE NETHERLANDS
Zena Werb, University of California, San Francisco, USA
Isaac P. Witz, Tel Aviv University, Israel
Arthur Zelent, Institute of Cancer Research, UK

For the most updated information, please visit our web site at www.csh-asia.org